Emerging options for the treatment of melanoma - focus on ipilimumab

被引:2
|
作者
Roddie, Claire [1 ]
Peggs, Karl S. [1 ]
机构
[1] UCL Canc Inst, Dept Hematol, Paul OGorman Bldg,72 Huntley St, London WC1E 6DD, England
来源
关键词
ipilimumab; cytotoxic-T-lymphocyte-antigen-4; advanced melanoma; metastatic; overall survival;
D O I
10.2147/ITT.S43522
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Ipilimumab is a fully human immunoglobulin subclass G1 anticytotoxic-Tlymphocyte- antigen-4 monoclonal antibody. It has been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency for use in advanced melanoma following clear evidence of survival benefit in randomized Phase III studies. It is also under investigation as a treatment for other solid tumors such as renal cell, lung, and prostate cancers. The purported mechanism of antitumor activity of ipilimumab is through T-cell activation, and the side effect profile reflects this. Immune-related adverse events (irAEs) affect 60% of treated patients and 15% are defined as severe. Fortunately, most irAEs are reversible with early diagnosis and correct management. FDA approval of ipilimumab is dependent on the careful execution of a risk evaluation and mitigation strategy, with the aim of increasing awareness amongst patients and clinicians of the immunological risks of treatment, and providing algorithms for management of irAEs as they develop. Ipilimumab is one of the first immunotherapies to become widely available in the setting of solid tumors, and ongoing research aims to elucidate optimal dosing, optimal scheduling, and expanded access to ipilimumab as an adjuvant or maintenance therapy where appropriate. The identification of clinical correlates or biomarkers to identify those likely to benefit from this high-cost therapy is a top priority.
引用
收藏
页码:67 / 78
页数:12
相关论文
共 50 条
  • [1] Emerging treatment options for myelofibrosis: focus on pacritinib
    Chow, Vivian
    Weissman, Ashley
    O'Connell, Casey Lee
    Mehrvar, Azim
    Akhtari, Mojtaba
    [J]. ONCOTARGETS AND THERAPY, 2016, 9 : 2655 - 2665
  • [2] Emerging Treatment Options for Myelofibrosis Focus on Anemia
    Sastow, Dahniel
    Tremblay, Douglas
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2023, 19 : 535 - 547
  • [3] Current and emerging treatment options for uveal melanoma
    Pereira, Patricia Rusa
    Odashiro, Alexandre Nakao
    Lim, Li-Anne
    Miyamoto, Cristina
    Blanco, Paula L.
    Odashiro, Macanori
    Maloney, Shawn
    De Souza, Dominique F.
    Burnier, Miguel N., Jr.
    [J]. CLINICAL OPHTHALMOLOGY, 2013, 7 : 1669 - 1682
  • [4] Ipilimumab in the treatment of melanoma
    Trinh, Van A.
    Hwu, Wen-Jen
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (06) : 773 - 782
  • [5] Ipilimumab for the treatment of melanoma
    Jain, Shikha
    Clark, Joseph I.
    [J]. MELANOMA MANAGEMENT, 2015, 2 (01) : 33 - 39
  • [6] Focus on current and emerging treatment options for glioma: A comprehensive review
    Lucke-Wold, Brandon
    Rangwala, Burhanuddin Sohail
    Shafique, Muhammad Ashir
    Siddiq, Mohammad Arham
    Mustafa, Muhammad Saqlain
    Danish, Fnu
    Nasrullah, Rana Muhammad Umer
    Zainab, Noor
    Haseeb, Abdul
    [J]. WORLD JOURNAL OF CLINICAL ONCOLOGY, 2024, 15 (04):
  • [7] Emerging treatment options in bipolar disorder in adolescents: focus on ziprasidone
    Khan, Afshan A.
    Strawn, Jeffrey R.
    Croarkin, Paul E.
    [J]. ADOLESCENT HEALTH MEDICINE AND THERAPEUTICS, 2010, 1 : 137 - 143
  • [8] Use of ipilimumab in the treatment of melanoma
    Acharya, Utkarsh H.
    Jeter, Joanne M.
    [J]. CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2013, 5 : 21 - 27
  • [9] FDA approves ipilimumab for treatment of melanoma
    不详
    [J]. BRITISH JOURNAL OF HOSPITAL MEDICINE, 2011, 72 (05) : 249 - 249
  • [10] Advances in Treatment of Metastatic Melanoma: Ipilimumab
    Rubin, Krista M.
    [J]. JOURNAL OF THE DERMATOLOGY NURSES ASSOCIATION, 2010, 2 (06) : 262 - 264